{"id":1068557,"date":"2024-08-03T02:35:31","date_gmt":"2024-08-03T06:35:31","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2024-08-18T11:48:51","modified_gmt":"2024-08-18T15:48:51","slug":"arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php","title":{"rendered":"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p><![CDATA[WESTLAKE VILLAGE, Calif., Aug.  02, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,000 restricted stock units of Arcutis\u2019 common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis\u2019 Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/08\/02\/2923822\/0\/en\/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\">Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068557","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068557"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068557"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068557\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}